Top Results For: wegovy

Currently, two generic versions of Ozempic and Wegovy are available for Canadians to purchase for patients who use it to treat diabetes or weight loss for a fraction of the cost.

Patients can receive the treatments at home for 'no additional cost' and will have the option of chatting with a pharmacist over the phone, Novo Nordisk said.

Ozempic and Wegovy, both produced by Novo Nordisk, currently cost hundreds of dollars a month, depending on the dosage dispensed, in some cases more than $450.

Health Canada approved both Dr. Reddy's and Apotex's generic semaglutide — the active ingredient in brand-name Ozempic and Wegovy — about three weeks ago.

It's the third generic semaglutide product approved by the department, though the first two were authorized for the treatment of Type 2 diabetes in adults.

Zepbound the now the only GLP-1 drug in Canada approved for the sleep disorder that causes people to stop breathing temporarily because their upper airway is blocked.

With a endoscopic sleeve gastroplasty, the stomach is stitched smaller from the inside and instead of doctors making abdominal incisions, the tools go down the patient's throat.

Canada is the first G7 country to authorize generic semaglutide. There are now seven other submissions currently under review for generic semaglutide by different companies.

Manufactured by Dr. Reddy’s Laboratories in India, the injectable medication has been approved for once-a-week treatment of Type 2 diabetes in adults.

The U.S. FDA said the drug was approved within 50 days of the company filing for approval, one of the fastest approval times for any drug.

Semaglutide, the active ingredient in GLP-1 drugs, was associated with a lower risk of worsening mental health, a study published in Lancet Psychiatry found.

Novo Nordisk says the expiration of its patents for some semaglutide GLP-1 drug treatments in markets like Canada will result in more generics and hurt sales.

Health Canada is warning Canadians of the dangers of buying "fake or unauthorized products" meant to replicate popular GLP-1 drugs such as Ozempic, Rybelsus and Wegovy.

The pill was approved by the U.S. Food and Drug Administration last month, a boon to Novo Nordisk as it looks to regain ground lost to U.S. rival Eli Lilly.

As of Dec. 29, Health Canada had received nine submissions seeking approval to make semaglutide, the active ingredient in Ozempic and Wegovy.

The once-a-day semaglutide pill is approved for reducing the risk of heart disease and Type 2 diabetes, the company said in a statement Monday.

The FDA approved the one-a-day Wegovy pill, the first oral GLP-1 medication for obesity in the U.S., Wegovy manufacturer Novo Nordisk said in a statement Tuesday.

The approval gives Novo Nordisk a leg up in the race to market a potent oral medication for shedding pounds as it looks to regain lost ground from rival Eli Lilly.

People on average regain weight at a rate of 0.4 kg/month after they stopped taking their weight loss medications, a review of 63 trials covering over 9,000 individuals showed.

Negotiations that could have led to coverage for weight-loss drug Wegovy under Canadian public health plans are not moving forward.